Newly Diagnosed Non-APL AML: Initial Treatment Selection by Fitness and Molecular Profile

Authored by Open Medicine, published on 2026-10-12 18:13:11.0

Assessment of patient characteristics

Assess: age and physiologic reserve; ECOG performance status; frailty and functional status; cardiac, pulmonary, renal, and hepatic function; major comorbidities; prior chemotherapy or radiotherapy; antecedent hematologic disease; infection and bleeding risk; treatment goals and patient preference. Do not use chronological age alone to define eligibility for intensive therapy. Identify urgent complications requiring immediate management, including leukostasis, tumor lysis risk, active infection, severe cytopenias, or coagulopathy. Before applying this pathway, exclude acute promyelocytic leukemia (APL). If APL is suspected, initiate ATRA promptly while confirmatory testing is underway.
- Comprehensive profiling of AML
  
  Perform comprehensive AML characterization before definitive treatment selection whenever clinically feasible: morphology; immunophenotyping; conventional cytogenetics; clinically indicated FISH; molecular profiling / myeloid NGS. Rapidly establish actionable disease-defining or treatment-relevant alterations, including: FLT3-ITD and FLT3-TKD IDH1 / IDH2 NPM1 TP53 RUNX1::RUNX1T1 CBFB::MYH11 KMT2A rearrangement other abnormalities required for current AML classification and risk stratification. For NPM1-mutated and core-binding-factor AML, establish a baseline molecular marker suitable for subsequent MRD assessment.
  - Patient eligible for intensive chemotherapy
    
    Consider intensive therapy when the anticipated benefit outweighs treatment-related risk. Integrate: physiologic reserve and performance status; comorbidity burden; organ function; disease biology; expected treatment sensitivity; patient goals. Fitness is not defined by age alone. Proceed to molecularly and biologically directed intensive treatment selection.
    - CBF-AML
      
      Confirm core-binding-factor AML: RUNX1::RUNX1T1; or CBFB::MYH11. CBF-AML is generally highly chemotherapy-sensitive and represents a favorable-risk AML category, although relapse risk varies according to disease biology and MRD response. Proceed to intensive chemotherapy incorporating gemtuzumab ozogamicin when clinically appropriate.
      - Intensive chemo + gemtuzumab
        
        For fit patients with CBF-AML, use intensive chemotherapy incorporating gemtuzumab ozogamicin (GO) when clinically appropriate. The survival benefit from adding GO to intensive therapy is greatest in AML with favorable cytogenetics, including CBF-AML. Regimen, GO schedule, cumulative dose, hepatic risk, and transplant planning should be individualized.
    - FLT3 mutation
      
      Establish whether the patient has: FLT3-ITD; or FLT3-TKD. For patients eligible for intensive chemotherapy, incorporate an appropriate frontline FLT3 inhibitor according to mutation subtype, regulatory availability, comorbidities, and local practice. Midostaurin has phase III evidence across FLT3-ITD and FLT3-TKD disease. Quizartinib has phase III evidence and regulatory approval specifically for newly diagnosed FLT3-ITD-positive AML.
      - Intensive chemo + FLT3 inhibitor
        
        Combine standard intensive induction/consolidation chemotherapy with a frontline FLT3 inhibitor. FLT3-ITD or FLT3-TKD - Midostaurin is an established option with intensive chemotherapy. FLT3-ITD - Quizartinib is an established option with induction and consolidation chemotherapy, followed by continuation therapy according to the approved regimen. Select the FLT3 inhibitor according to mutation subtype, toxicity profile, drug interactions, QT risk, access, and local approval.
    - Others
      
      In this faculty framework, this branch includes patients appropriate for conventional intensive induction who do not have CBF-AML or FLT3-mutated AML and who do not have disease features directing an alternative approach. Standard intensive induction commonly uses an anthracycline plus cytarabine (7+3), with regimen selection individualized according to AML biology and patient characteristics. Important nuance: therapy-related AML and AML with myelodysplasia-related features do not automatically make a patient physiologically ineligible for intensive therapy. Selected fit patients may be candidates for intensive approaches such as CPX-351.
      - Intensive chemo (i.e., 7+3)
        
        Consider conventional intensive induction with: 7 days of cytarabine + 3 days of an anthracycline (7+3). Treatment should be individualized according to AML subtype, cytogenetic/molecular risk, comorbidities, prior therapy, and local standards. This node represents initial induction only. Consolidation, MRD-directed decisions, and transplant strategy are outside the scope of this pathway.
  - Patient ineligible for intensive chemotherapy
    
    Consider a non-intensive treatment strategy when intensive induction is unlikely to provide an acceptable risk-benefit balance because of: advanced age together with reduced physiologic reserve; major comorbidity; poor performance status or frailty; relevant organ dysfunction; disease biology associated with limited expected benefit from conventional intensive chemotherapy; patient preference. HMA + venetoclax is an established frontline backbone for many patients ineligible for intensive chemotherapy, but molecularly defined alternatives or clinical-trial strategies may be appropriate.
    - FLT3
      
      Confirm FLT3 mutation subtype and mutation burden. HMA + venetoclax remains an established non-intensive backbone. The addition of gilteritinib to an HMA/venetoclax backbone has produced high response rates and deep molecular responses in early-phase frontline studies but should currently be regarded as a selected / emerging strategy rather than a universal standard. Gilteritinib + azacitidine without venetoclax increased response rate but did not improve overall survival in the randomized LACEWING trial.
      - HMA / gilteritinib / venetoclax
        
        Established backbone: HMA + venetoclax. Selected / emerging FLT3-directed strategy: HMA + venetoclax + gilteritinib may be considered in expert centers or clinical trials for selected newly diagnosed FLT3-mutated AML. Do not interpret this node as establishing gilteritinib + HMA alone as preferred standard frontline therapy. Closely manage prolonged myelosuppression, infections, drug interactions, and venetoclax duration.
    - IDH1/2
      
      Determine whether the actionable alteration is IDH1 or IDH2, because the strength of frontline evidence differs. IDH1-mutated AML ivosidenib + azacitidine is an established frontline option for patients unsuitable for intensive therapy; HMA + venetoclax is also an established option. IDH2-mutated AML HMA + venetoclax is an established frontline approach; enasidenib + azacitidine has demonstrated significant clinical activity but does not have the same phase III / frontline regulatory evidence as ivosidenib + azacitidine. Triplet HMA + venetoclax + IDH inhibitor strategies should be considered selected/emerging or clinical-trial approaches.
      - IDH1/2 inhibitor + HMA +/- venetoclax
        
        IDH1-mutated AML Ivosidenib + azacitidine is an established evidence-based frontline option in patients unsuitable for intensive chemotherapy. HMA + venetoclax is also reasonable. IDH2-mutated AML HMA + venetoclax is an established frontline option. Enasidenib + azacitidine is evidence-supported but should be interpreted according to local approval and availability. HMA + venetoclax + an IDH inhibitor should be considered a selected / emerging strategy rather than a universal standard. Monitor for differentiation syndrome with IDH inhibitors and for prolonged cytopenias with venetoclax-based combinations.
    - MLL/KMT2A/NPM1
      
      Use current nomenclature: KMT2A-rearranged AML NPM1-mutated AML These leukemias are biologically dependent on the menin-KMT2A interaction and may be sensitive to menin inhibition. In patients unsuitable for intensive chemotherapy, HMA + venetoclax remains a recognized frontline backbone. Upfront incorporation of a menin inhibitor is promising but remains an emerging / clinical-trial strategy.
      - HMA / menin inhibitor / venetoclax
        
        Current established backbone: HMA + venetoclax. For NPM1-mutated or KMT2A-rearranged AML, HMA + venetoclax + a menin inhibitor is a promising biologically directed strategy with encouraging early frontline data. Frontline menin-inhibitor combinations remain investigational / clinical-trial strategies. When a menin inhibitor is used, monitor for: differentiation syndrome; QT prolongation where applicable; cytopenias; clinically important CYP-mediated drug interactions.
    - Multi-hit TP53
      
      Confirm TP53 mutation status, variant allele frequency, cytogenetic context, and evidence of complex or monosomal karyotype. TP53-mutated AML has a particularly poor prognosis across currently available frontline approaches. Clinical trial should be prioritized whenever feasible. If a trial is not available, an HMA-based approach is reasonable. HMA + venetoclax can increase response rates, but durable survival benefit in TP53-mutated AML remains limited.
      - HMA
        
        Clinical trial is preferred whenever feasible for TP53-mutated AML. If a trial is unavailable, consider an HMA-based strategy, such as azacitidine or decitabine, individualized according to performance status, cytopenias, infection risk, goals of care, and local practice. The addition of venetoclax may increase remission rates but has not overcome the adverse biology of TP53-mutated AML. Reassess early for response, tolerability, and opportunities for trial enrollment or transplant in highly selected responding patients.
    - T-AML / AML-MRC / Others
      
      This branch applies to patients who are ineligible for intensive chemotherapy and have: therapy-related AML; AML with myelodysplasia-related features; secondary AML; or other AML without a more compelling molecularly targeted strategy. Current classifications increasingly use AML with myelodysplasia-related (AML-MR) terminology rather than the historical term AML-MRC. For patients in this non-intensive branch, HMA + venetoclax is an established frontline option. Selected fit patients with therapy-related AML or AML-MR may instead be candidates for intensive CPX-351; therefore disease subtype alone should not be equated with physiologic unfitness.
      - HMA + venetoclax
        
        Use an HMA + venetoclax backbone for newly diagnosed AML in patients unsuitable for intensive chemotherapy when no more appropriate molecularly directed approach is selected. Common HMA backbones include: azacitidine; decitabine. Individualize venetoclax duration according to marrow response, cytopenias, infection risk, concomitant CYP3A inhibitors, and subsequent cycles. Perform early marrow assessment to guide venetoclax interruption and subsequent cycle duration. Provide tumor lysis prophylaxis, antimicrobial/supportive care, and close blood-count monitoring.
    - Monocytic / RAS
      
      Identify: - monocytic / myelomonocytic differentiation; and/or - clinically relevant NRAS/KRAS pathway alterations. Monocytic differentiation and RAS-pathway mutations have been associated with reduced sensitivity to venetoclax-based therapy in biologic and clinical datasets. Within this faculty framework, these features prompt consideration of a cladribine/cytarabine/venetoclax-based approach. This is a selected / institution-specific strategy rather than a validated RAS-specific standard of care.
      - Ara-C / cladribine / venetoclax
        
        Consider a cladribine + cytarabine + venetoclax-based non-anthracycline regimen in selected patients. In published frontline studies in older or less-fit AML, this strategy has commonly used cladribine + low-dose cytarabine + venetoclax, with some protocols alternating with azacitidine + venetoclax. Phase II data demonstrate high response rates in newly diagnosed older/unfit AML. However, this approach has not been prospectively validated specifically for monocytic or RAS-mutated AML and should therefore be presented as a selected expert strategy rather than a biomarker-defined standard. Clinical-trial participation is encouraged whenever available.

tos privacy Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345-1377. doi:10.1182/blood.2022016867 DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. doi:10.1056/NEJMoa2012971.Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014;15(9):986-996. doi:10.1016/S1470-2045(14)70281-5.Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454-464. doi:10.1056/NEJMoa1614359.Erba HP, Montesinos P, Kim HJ, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-ITD-positive acute myeloid leukaemia (QuANTUM-First). Lancet. 2023;401(10388):1571-1583. doi:10.1016/S0140-6736(23)00464-6.Lancet JE, Uy GL, Cortes JE, et al. CPX-351 versus 7+3 cytarabine and daunorubicin in older patients with newly diagnosed secondary AML. J Clin Oncol. 2018;36(26):2684-2692.Short NJ, Daver N, DiNardo CD, et al. Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML. J Clin Oncol. 2024;42(13):1499-1508. doi:10.1200/JCO.23.01911.Wang ES, Montesinos P, Minden MD, et al. Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3-mutated AML ineligible for intensive chemotherapy. Blood. 2022;140(17):1845-1857. doi:10.1182/blood.2021014586. Final 2026 reporting remained consistent with the lack of OS superiority.Montesinos P, Recher C, Vives S, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519-1531. doi:10.1056/NEJMoa2117344.DiNardo CD, Schuh AC, Stein EM, et al. Enasidenib plus azacitidine versus azacitidine alone in newly diagnosed mutant-IDH2 acute myeloid leukaemia. Lancet Oncol. 2021;22(11):1597-1608. doi:10.1016/S1470-2045(21)00494-0.Zeidner JF, Lin TL, Welkie RL, et al. Azacitidine, venetoclax, and revumenib for newly diagnosed NPM1-mutated or KMT2A-rearranged AML. J Clin Oncol. 2025;43(23):2606-2615. doi:10.1200/JCO-25-00914.Pollyea DA, Pratz KW, Wei AH, et al. Outcomes in patients with poor-risk cytogenetics with or without TP53 mutations treated with venetoclax and azacitidine. Clin Cancer Res. 2022;28(24):5272-5279. doi:10.1158/1078-0432.CCR-22-1183.Kadia TM, Reville PK, Wang X, et al. Phase II study of venetoclax added to cladribine plus low-dose cytarabine alternating with 5-azacitidine in older patients with newly diagnosed AML. J Clin Oncol. 2022;40(33):3848-3857. doi:10.1200/JCO.21.02823.Sango J, Carcamo S, Sirenko M, et al. RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax. Nature. 2024;636:241-250. doi:10.1038/s41586-024-08137-x.